Transitional cell carcinoma epidemiology and demographics

Transitional cell carcinoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Transitional cell carcinoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Cystoscopy and Bladder Biopsy
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Transitional cell carcinoma epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Transitional cell carcinoma epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Transitional cell carcinoma epidemiology and demographics
CDC on Transitional cell carcinoma epidemiology and demographics
Transitional cell carcinoma epidemiology and demographics in the news
Blogs on Transitional cell carcinoma epidemiology and demographics
Directions to Hospitals Treating Transitional cell carcinoma
Risk calculators and risk factors for Transitional cell carcinoma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Epidemiology and Demographics

• Transitional cell carcinoma of the renal pelvis, accounts for only 7% of all kidney tumors.
• Transitional cell cancer of the ureter, accounts for only 1 of every 25 upper tract tumors.
• They are curable in more than 90% of patients if they are superficial and confined to the renal pelvis or ureter.
• Patients with deeply invasive tumors that are still confined to the renal pelvis or ureter have a 10% to 15% likelihood of cure.
• Patients with tumors with penetration through the urothelial wall or with distant metastases usually cannot be cured with currently available forms of treatment.

Age

Transitional cell carcinoma is typically a tumor of older patients, with the average age of presentation being 65, and the majority of patients being over the age of 60.

Gender

There is a strong male predilection (M:F = 4:1), at least in part due to many tumors (especially historically) having been due to industrial exposure.